

RECEIVED
NOV 2 1999
TECH CENTER 1600/2900

IN THE CLAIMS:

Cancel claim 22.

Amend claims 15, 16 and 21 as follows:


C1 15. (Twice amended) A method for improving inhibition of gastric acid secretion comprising administering to a patient in need thereof the oral pharmaceutical formulation as claimed in any of claims 7-10 or 21.

16. (Twice amended) A method for improving the treatment of gastrointestinal disorders associated with excess acid secretion comprising administering to a patient in need thereof the oral pharmaceutical formulation as claimed in any of claims 7-10 or 21.

In claim 21, delete "or 19".

Add new claims 23-25:


C3 23. The oral pharmaceutical formulation according to claim 19, wherein the H^+ , K^+ -ATPase inhibitor is a compound of the formula I




wherein

Het₁ is


03
Cen




or




Het₂ is




or



X =



or



wherein

N in the benzimidazole moiety means that one of the ring carbon atoms substituted by R₆-R₉ optionally may be exchanged for a nitrogen atom without any substituents;

R₁, R₂ and R₃ are the same or different and selected from the group consisting of hydrogen, alkyl, alkoxy, fluorine-substituted alkoxy, alkylthio, alkoxyalkoxy, dialkylamino, piperidino, morpholino, halogen, phenyl and phenylalkoxy;

R₄ and R₅ are the same or different and selected from the group consisting of hydrogen, alkyl and aralkyl;